Point-of-Care-Testing (POCT) Market Report 2025

The point-of-care-testing (POCT) market size has grown rapidly in recent years. It will grow from $45.45 billion in 2024 to $50.79 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historical period can be attributed to a growing focus on personalized medicine, increasing investments in healthcare infrastructure, a rise in emergency care cases, expanded use of point-of-care molecular testing, and greater integration of AI in diagnostics.

The point-of-care-testing (POCT) market size is expected to see rapid growth in the next few years. It will grow to $78.19 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth during the forecast period can be attributed to increasing demand for personalized medicine, expanding telehealth and remote monitoring trends, rising healthcare access in emerging markets, broader application in non-traditional settings, and growing adoption of wearable diagnostic devices. Key trends expected in the forecast period include advancements in multiplex testing platforms, development of portable molecular diagnostic devices, innovations in smartphone-based diagnostic tools, improvements in connectivity and data integration, and the emergence of AI-powered POCT solutions.

The increasing adoption of telemedicine is expected to drive growth in the point-of-care testing (POCT) market. Telemedicine delivering healthcare remotely via video calls, phone, or secure messaging has gained traction due to rising demand for convenient, timely, and contact-free care, a trend accelerated by the COVID-19 pandemic. POCT complements telemedicine by enabling rapid, reliable diagnostic results that can be shared instantly with remote healthcare providers. For example, a February 2023 survey by Rock Health of 8,014 respondents found that 76% of individuals over 55 had used telemedicine, and 80% of all participants had accessed care remotely at least once, up 8% from 2021.

Companies in the POCT market are leveraging smart device-enabled solutions to improve workflow efficiency, decision support, and patient outcomes in near-patient settings. Blood glucose management solutions, for instance, allow for real-time monitoring and control of blood sugar levels in patients with diabetes. In January 2022, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, launched the Cobas Pulse system, a connected platform combining advanced POCT blood glucose testing with smart device integration. The system enables automatic result transfer to hospital IT systems and supports clinical decision-making through healthcare apps, streamlining near-patient diagnostics.

In August 2024, Quest Diagnostics Inc., a US-based medical laboratory company, acquired LifeLabs LP for $1 billion (CAN $1.35 billion). This acquisition expands Quest Diagnostics’ POCT offerings and strengthens access to innovative diagnostic solutions. LifeLabs LP is a Canada-based provider of point-of-care testing services.

Major players in the point-of-care-testing (POCT) market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company, Zoetis Inc., BioMérieux SA, QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Nova Biomedical Corporation, LifeScan Inc., Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Trinity Biotech Plc, SiPhox Inc., and Sinocare Inc.

North America was the largest region in the point-of-care testing (POCT) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in point-of-care testing (POCT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the point-of-care testing (POCT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Point-of-care testing (POCT) refers to diagnostic testing conducted at or near the site of patient care, providing immediate results and enabling faster clinical decision-making. Its purpose is to deliver quick and accurate diagnostic information directly at the point of care, facilitating timely treatment and improved patient outcomes.

The primary types of point-of-care testing (POCT) include blood glucose testing, infectious disease testing, cardiac marker testing, coagulation testing, pregnancy and fertility testing, blood gas or electrolyte testing, urinalysis testing, and others. Blood glucose testing involves measuring the amount of sugar (glucose) in a person’s blood to monitor and manage related conditions. POCT products are available through various purchase modes, including over-the-counter and prescription-based products, and utilize technologies such as immunoassays, molecular diagnostics, microbial detection, polymerase chain reaction (PCR) testing, and biochemical testing. Key end users include clinical laboratories, ambulatory care facilities, physician offices, pharmacies, retail clinics, e-commerce platforms, hospitals, critical care centers, urgent care centers, home care and self-testing, and others.

The point-of-care-testing (POCT) market research report is one of a series of new reports that provides point-of-care-testing (POCT) market statistics, including the point-of-care-testing (POCT) industry global market size, regional shares, competitors with the point-of-care-testing (POCT) market share, detailed point-of-care-testing (POCT) market segments, market trends, and opportunities, and any further data you may need to thrive in the point-of-care-testing (POCT) industry. This point-of-care-testing (POCT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The point-of-care testing (POCT) market includes revenues earned by entities by providing services such as on-site diagnostic testing, rapid disease detection, mobile health screening, and patient self-testing support. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care testing (POCT) market includes sales of portable HbA1c analyzers, handheld blood gas analyzers, CRP (C-reactive protein) test kits, multiplex respiratory pathogen detection kits, and lateral flow urine analysis devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.